netFormulary NHS
North Staffordshire Joint Formulary
North Staffordshire Clinical Commissioning Group
Stoke-on-Trent Clinical Commissioning Group
 Search
 Formulary Chapter 11: Eye - Full Chapter
11.04.01  Expand sub section  Corticosteroids
Betamethasone  
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Betamethasone sodium phosphate 0.1% eye/ear/nose drops
Betamethasone (Betnesol) 0.1% eye ointment

 
   
Dexamethasone  (Maxidex®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Dexamethasone 0.1% eye drops 
Minims Dexamethasone sodium phosphate 0.1% eye drops (0.5ml unit dose)

 
   
Fluorometholone (FML®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Fluorometholone 0.1% opthalmic suspension

 
   
Prednisolone  
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Amber

Predsol®- Prednisolone sodium phosphate 0.5% ear/eye drops
Pred Forte®- Prednisolone acetate 1% eye drops
Minims Prednisolone sodium phosphate 0.5% ear/eye drops (0.5ml unit dose)

 
   
Rimexolone (Vexol®)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber

Rimexolone 1% opthalmic suspension

Restriction: 2nd line treatment when other topical corticosteroids have failed

Discontinued in 2016.
Opthalmology to consider Lotoprednol 0.5% eyedrops post-op in patients who have previously developed a disproportionate increase in intra ocular pressure when treated with traditional corticosteroids 

 
   
Dexamethasone  (Ozurdex®)
(Intravitreal implant)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG
BlueTeq

Ozurdex® 700micrograms intravitreal implant

Restriction: In line with NICE Guidance only

HCD

 
Link  NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Link  NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Link  NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
   
Fluocinolone acetonide
(Iluvien®)
(Intravitreal implant)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
CCG

Iluvien® 190micrograms intravitreal implant

Restriction: In line with NICE Guidance only

 

 
Link  NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Link  NICE TA590:Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
   
Adalimumab  (Hyrimoz®, Amgevita®, Imraldi®, Hulio®, Humira®)
(Prescribe by brand)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
NHS England

Restriction: In line with NICE Guidance only

Clinicians must ensure the biosimilar brand for their region is prescribed first-line.
(Hyrimoz is the first line biosimilar in West Midlands region; Amgevita is used in patients intolerant to citrate content i.e injection site reactions)

 
Link  NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG
Blueteq
High Cost Drug Approval System

Traffic Light Status Information

Status Description

Red

Medicines that can only be prescribed within Secondary Care. Examples of medicines which fall into this category are: Certain new medicines and new indications for older medicines where there is at present no experience of use in Primary Care. Medicines or dressings not available or prescribable in Primary Care. Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available   

Amber

Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.   

Amber E

Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary  

Green

Medicines which can be prescribed in either Primary or Secondary Care.  

Grey

These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary. Inadequate or weak evidence for efficacy No clearly defined local need Lack of long term safety data No perceived benefit over established formulary alternatives Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or not tolerated.  

netFormulary